Vandortuzumab vedotin
Vandortuzumab Vedotin (RG7450): A Potential Therapeutic Agent for Cancer[edit | edit source]
Vandortuzumab Vedotin (RG7450) is a humanized monoclonal antibody that was specifically engineered with the intention of treating various forms of cancer. Created through biotechnological advancements, its development underscores the growing interest and investment in targeted therapies within the oncology field.
Background[edit | edit source]
- Classification: Humanized monoclonal antibody.
- Primary Objective: Treatment of cancer.
Mechanism of Action[edit | edit source]
Vandortuzumab Vedotin, like other antibody-drug conjugates, is designed to selectively target cancer cells. It combines the specific targeting capabilities of monoclonal antibodies with the cytotoxic potency of small-molecule drugs. By honing in on cancer cells and delivering a potent drug payload, the compound seeks to eliminate tumor cells while sparing healthy tissue, thereby reducing systemic side effects[1].
Developer Information[edit | edit source]
- Company: Vandortuzumab Vedotin was developed through a collaboration between Genentech and Roche, two leaders in the biopharmaceutical industry.
Clinical Development and Outcome[edit | edit source]
- Research Phase: Vandortuzumab Vedotin underwent various stages of clinical trials to assess its safety, efficacy, and potential therapeutic applications in oncology.
- Discontinuation: In 2017, the development of Vandortuzumab Vedotin was halted. The exact reasons for discontinuation often encompass a range of factors, from observed side effects to economic considerations or strategic focuses of the developing company[2].
Implications[edit | edit source]
The development and subsequent discontinuation of Vandortuzumab Vedotin emphasizes the complexities and challenges inherent in drug development. While many compounds enter clinical trials, a significantly smaller number achieve market approval. However, each attempt contributes to the broader understanding of disease mechanisms and therapeutic interventions, potentially paving the way for future innovations[3].
Conclusion[edit | edit source]
Vandortuzumab Vedotin stands as a testament to the continuous efforts within the pharmaceutical industry to innovate and improve therapeutic options for patients with cancer. Although this specific compound did not progress to market, the knowledge gained from its development remains invaluable for future research endeavors.
References[edit | edit source]
- ↑ Jones RL, et al. Antibody-drug conjugates in solid tumors: a look into novel targets. Journal of Hematology & Oncology. 2021;14(1):1-14.
- ↑ Thomson Reuters. Discontinuation of clinical trials – reasons, challenges, and guidance. PLoS ONE. 2018;13(8):e020 in006.
- ↑ Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov. 2004;3(8):711-715.
 | This monoclonal antibody–related article is a stub. You can help WikiMD by expanding it. |
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
